Novel monoclonal antibodies for cancer treatment: The trifunctional an-tibody catumaxomab (Removab®)

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 309-316

  Seimetz, Diane ^a  

^a Fresenius Biotech   (Germany)

Author keywords

Anti CD3; Anti EpCAM; Catumaxomab; Epithelial cell adhesion molecule (EpCAM); Malignant ascites; Targeted cancer immunotherapy; Trifunctional antibody

Indexed keywords

CATUMAXOMAB; CD16 ANTIGEN; CD3 ANTIGEN; DIURETIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; FC RECEPTOR; FC RECEPTOR IIA;

ABDOMINAL PAIN; ACCESSORY CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ASCITES; CANCER THERAPY; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; MACROPHAGE; MALIGNANT ASCITES; MAXIMUM PLASMA CONCENTRATION; NATURAL KILLER CELL; NAUSEA; PARACENTESIS; PATHOPHYSIOLOGY; PERITONEUM VEIN SHUNT; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; T LYMPHOCYTE; TUMOR CELL; VOMITING;

EID: 83655196673     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.309     Document Type: Review

References (37)

1. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95.
2. Chames P, Baty D. Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 2009;12:276-83.
3. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-31.
4. Ruf P, Gires O, Jäger M, et al. Characterisation of the new Ep-CAM-specific antibody HO-3: implications for trifunctional an-tibody immunotherapy of cancer. Br J Cancer 2007;97:315-21.
5. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous acti-vation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumour cell killing. J Immunol 1999;163:1246-52.
6. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6.
7. Riesenberg R, Buchner A, Pohla H, et al. Lysis of prostate car-cinoma cells by trifunctional bispecific antibodies (αEp-CAM × αCD3). J Histochem Cytochem 2001;49:911-7.
8. Schmitt M, Schmitt A, Reinhardt P, et al. Opsonization with a trifunctional bispecific (αCD3 × αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumour cells by cytotoxic T lymphocytes. Int J Oncol 2004;25:841-8.
9. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007;18:945-9.
10. Parsons SL, Watson SA, Steele RJC. Malignant ascites. Br J Surgery 1996;83:6-14.
11. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006;42:589-97.
12. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996;6:474-80.
13. Parsons SL, Lang MW, Steel RJC. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996;22:237-9.
14. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg 2004;198:999-1011.
15. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyper-permeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
16. Nagy JA, Morgan ES, Herzberg KT, et al. Pathogenesis of asci-tes tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995;55:376-85.
17. Tamsma J. The pathogenesis of malignant ascites. Cancer Treat Res 2007;134:109-18.
18. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies: evaluation of five epithelial markers. Virchows Archiv 1999;435:43-9.
19. De Angelis M, Buley ID, Heryet A, et al. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 1992;3:111-7.
20. Diaz-Arias AA, Loy TS, Bickel JT, et al. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocyto-chemical study of 232 cases. Diagn Cytopathol 1993;9:516-21.
21. Passebosc-Faure K, Li G, Lambert C, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous ef-fusions. Clin Cancer Res 2005;11:6862-7.
22. Freedman RS, Deavers M, Liu J, et al. Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2004;2:23.
23. Kubicka U, Olszewski WL, Tarnowski W, et al. Normal human immune peritoneal cells: subpopulations and functional char-acteristics. Scand J Immunol 1996;44:157-63.
24. Burges A, Wimberger P, Kümper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905.
25. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209-21.
26. Belau A, Pfisterer J, Wimberger P, et al. Randomized, multi-center, two-dose level, open-label, phase IIa study with the in-traperitoneally infused trifunctional bispecific antibody ca-tumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol 2007;25(Suppl):Abstract5556.
27. Ströhlein MA, Lordick F, Rüttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie 2011;34:101-8.
28. Stroehlein M, Schemanski O, Jaeger M, et al. Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with advanced gastric, colon, and pancreatic cancer: a pilot phase I study (Abstract 120). Orlando, Florida, USA: ASCO GI Cancers Symposium. 2008.
29. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004;96:990-7.
30. [Internet] Removab Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/removab/H-972-PI-en.pdf.
31. Ströhlein MA, Essing MM, Schmidt-Rimpler C, et al. Ca-tumaxomab treatment significantly improves overall survival in patients with malignant ascites: follow-up results from a pivotal phase II/III study (Abstract AB1272). Paris, France: 22nd International Congress on Anti-Cancer Treatment. 2011.
32. Jeyarajah DR, Thistlethwaite JR Jr. General aspects of cyto-kine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993;25:16-20.
33. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syn-drome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-24.
34. DeNardo GL, Bradt BM, Mirick GR, et al. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 2003;52:309-16.
35. Marmé A, Strauss G, Bastert G, et al. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002;101:183-9.
36. Azinovic I, DeNardo GL, Lamborn KR, et al. Survival benefit associated with human anti-mouse antibody (HAMA) in pa-tients with B-cell malignancies. Cancer Immunol Immunother 2006;55:1451-8.
37. Ott MG, Lindhofer H, Linke RG, et al. The trifunctional anti-body catumaxomab: correlation between immunological re-sponse and clinical outcome - new analysis of a pivotal phase II/III study. J Clin Oncol 2010;28(Suppl):Abstract2551.